SCHEMBL7203984

SCHEMBL7203984

NC(=O)N1CCC(S(=O)(=O)c2ccc(OCc3ccccc3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 10/20 0.45
MMP13 P45452 8/20 0.45
ADAMTS4 O75173 4/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
RORC P51449 4/20 0.42
ADAM17 P78536 4/20 0.42
MMP9 P14780 2/20 0.41
MMP2 P08253 1/20 0.41
MMP14 P50281 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
PARP10 Q53GL7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7202584 0.92 RORC (0.46) MMP1MMP13ADAMTS4RORCADAM17
SCHEMBL7205347 0.92 MMP1 (0.56) MMP1MMP13ADAMTS4NPC1RAB9A
SCHEMBL7205273 0.92 MMP1 (0.56) MMP1MMP13ADAMTS4ADAM17MMP9
SCHEMBL7205420 0.92 MMP1 (0.45) MMP1MMP13ADAMTS4CA12CA1
SCHEMBL7205312 0.92 MMP1 (0.47) MMP1MMP13ADAMTS4NPC1RAB9A
SCHEMBL7200563 0.90 MMP1 (0.57) MMP1MMP13ADAMTS4ADAM17MMP9
SCHEMBL7201801 0.90 MMP1 (0.57) MMP1MMP13ADAMTS4ADAM17
SCHEMBL7200542 0.90 ADAMTS4 (0.42) MMP1MMP13ADAMTS4RAB9ARORC
SCHEMBL7201593 0.90 MAOB (0.49) MMP1MMP13ADAM17MMP9MMP2
SCHEMBL7201220 0.89 MMP1 (0.47) MMP1MMP13NPC1RAB9AADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885ADAMTS4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.